Abstract
For many years, there has been an ongoing search for new compounds that can selectively alter gene expression as a new way to treat human disease by addressing targets that are otherwise “undruggable” with traditional pharmaceutical approaches involving small molecules or proteins. RNA interference (RNAi) strategies have raised a lot of attention and several compounds are currently being tested in clinical trials. Viruses are the obvious target for RNAitherapy, as most are difficult to treat with conventional drugs, they become rapidly resistant to drug treatment and their genes differ substantially from human genes, minimizing side effects. Antisense strategy offers very high target specificity, i.e., any viral sequence could potentially be targeted using the complementary oligonucleotide sequence. Consequently, new antisense-based therapeutics have the potential to lead a revolution in the anti-infective drug development field. Additionally, the relatively short turnaround for efficacy testing of potential RNAi molecules and that any pathogen is theoretically amenable to rapid targeting, make them invaluable tools for treating a wide range of diseases. This review will focus on some of the current efforts to treat infectious disease with RNAi-based therapies and some of the obstacles that have appeared on the road to successful clinical intervention.
Keywords: RNAi, infectious disease, siRNA, antiviral, therapy
Infectious Disorders - Drug Targets
Title: RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease
Volume: 8 Issue: 4
Author(s): M. Lopez-Fraga, N. Wright and A. Jimenez
Affiliation:
Keywords: RNAi, infectious disease, siRNA, antiviral, therapy
Abstract: For many years, there has been an ongoing search for new compounds that can selectively alter gene expression as a new way to treat human disease by addressing targets that are otherwise “undruggable” with traditional pharmaceutical approaches involving small molecules or proteins. RNA interference (RNAi) strategies have raised a lot of attention and several compounds are currently being tested in clinical trials. Viruses are the obvious target for RNAitherapy, as most are difficult to treat with conventional drugs, they become rapidly resistant to drug treatment and their genes differ substantially from human genes, minimizing side effects. Antisense strategy offers very high target specificity, i.e., any viral sequence could potentially be targeted using the complementary oligonucleotide sequence. Consequently, new antisense-based therapeutics have the potential to lead a revolution in the anti-infective drug development field. Additionally, the relatively short turnaround for efficacy testing of potential RNAi molecules and that any pathogen is theoretically amenable to rapid targeting, make them invaluable tools for treating a wide range of diseases. This review will focus on some of the current efforts to treat infectious disease with RNAi-based therapies and some of the obstacles that have appeared on the road to successful clinical intervention.
Export Options
About this article
Cite this article as:
Lopez-Fraga M., Wright N. and Jimenez A., RNA Interference-Based Therapeutics: New Strategies to Fight Infectious Disease, Infectious Disorders - Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187152608786734223
DOI https://dx.doi.org/10.2174/187152608786734223 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structural Heterogeneity and Multifunctionality of Lactoferrin
Current Protein & Peptide Science Viral Protein Functions Study by Affinity Modification
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Protein Peptide Informatics and Drug Designing - Some Computational Techniques for Structural Genomics Based Approaches (Part II) (Guest Editor: Rajani R. Joshi)]
Protein & Peptide Letters Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Neurovirulence of SARS CoV2: From Clinical Data to Preclinical Neuropsychological Exploration
Coronaviruses Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience Ketogenic Diets in the Treatment of Epilepsy
Current Pharmaceutical Design Antiviral Drug Discovery Targeting to Viral Proteases
Current Pharmaceutical Design The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Evasion of Host Immunity by Virulent Salmonella: Implications for Vaccine Design
Current Medicinal Chemistry The Recent Progress in RSV Vaccine Technology
Recent Patents on Anti-Infective Drug Discovery Antidepressants and Sleep: Neurophysiology and Clinical Correlates
Current Psychiatry Reviews A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease
Current Drug Targets Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Hepatitis C Virus Proteins as Targets for Drug Development: The Role of Bioinformatics and Modelling
Current Drug Targets Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges
Current Neuropharmacology Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry Ex Vivo Liver – Directed Gene Therapy for the Treatment of Metabolic Diseases: Advances in Hepatocyte Transplantation and Retroviral Vectors
Current Gene Therapy Novel Therapies for Cytomegalovirus Disease
Recent Patents on Anti-Infective Drug Discovery